Literature DB >> 29679773

Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation.

Michael Scordo1, Sejal M Morjaria2, Eric R Littmann3, Ankush Bhatia4, Helen H Chung5, Molly Maloy6, Lisa M DeAngelis7, Sergio A Giralt8, Ying Taur2, Craig S Sauter8.   

Abstract

We investigated the incidence of viral, fungal, bacterial, and parasitic infections observed in 57 patients with central nervous system lymphoma after thiotepa, busulfan, and cyclophosphamide-conditioned autologous stem cell transplantation (TBC-ASCT) and 79 patients with systemic non-Hodgkin lymphoma after traditional carmustine, etoposide, cytarabine, and melphalan-conditioned ASCT (BEAM-ASCT). Twenty of 57 (35%) TBC-ASCT patients had detectable viremia with human herpesvirus 6, cytomegalovirus, adenovirus, or BK virus, versus 9 of 79 (11%) BEAM-ASCT patients. Eight TBC-ASCT patients had clinically relevant viral infections (4 human herpesvirus 6, 2 cytomegalovirus, 1 adenovirus, 2 BK virus), versus 0 in the BEAM-ASCT group. Four TBC-ASCT patients suffered infections from either a fungal or parasitic pathogen versus 1 BEAM-ASCT patient. TBC was associated with greater risk of viral reactivation compared with BEAM, independent of other factors (hazard ratio, 4.42; 95% confidence interval, 1.9 to 11.3; P < .001). Prolonged lymphopenia and steroid use in the peri- and post-ASCT period did not explain these observed differences. The pathogenesis of these unusual infections in TBC-ASCT patients remains incompletely understood, and may involve more potent immune suppression with TBC conditioning. Clinicians should be aware of these differences in infection risk in TBC-ASCT patients, which more closely parallel those seen in allogenic hematopoietic cell transplantation recipients. New prophylactic approaches to help minimize these infections should be considered in this population.
Copyright © 2018 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Central nervous system lymphoma; Diffuse large B cell lymphoma; High-dose therapy and autologous stem cell transplantation; Infectious complications

Mesh:

Substances:

Year:  2018        PMID: 29679773      PMCID: PMC6163063          DOI: 10.1016/j.bbmt.2018.04.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  23 in total

1.  Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center study.

Authors:  Francesco Marchesi; Fulvia Pimpinelli; Svitlana Gumenyuk; Daniela Renzi; Francesca Palombi; Francesco Pisani; Atelda Romano; Antonio Spadea; Elena Papa; Marco Canfora; Fabrizio Ensoli; Andrea Mengarelli
Journal:  World J Transplant       Date:  2015-09-24

2.  R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Authors:  Antonio Omuro; Denise D Correa; Lisa M DeAngelis; Craig H Moskowitz; Matthew J Matasar; Thomas J Kaley; Igor T Gavrilovic; Craig Nolan; Elena Pentsova; Christian C Grommes; Katherine S Panageas; Raymond E Baser; Geraldine Faivre; Lauren E Abrey; Craig S Sauter
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

3.  High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.

Authors:  Zachariah DeFilipp; Shuli Li; Areej El-Jawahri; Philippe Armand; Lakshmi Nayak; Nancy Wang; Tracy T Batchelor; Yi-Bin Chen
Journal:  Cancer       Date:  2017-04-03       Impact factor: 6.860

4.  Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.

Authors:  Gregory M Cote; Ephraim P Hochberg; Alona Muzikansky; Fred H Hochberg; Jan Drappatz; Steven L McAfee; Tracy T Batchelor; Ann S LaCasce; David C Fisher; Jeremy S Abramson; Philippe Armand; Yi-Bin Chen
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-13       Impact factor: 5.742

5.  High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.

Authors:  David Qualls; Andrew Sullivan; Shuli Li; Andrew M Brunner; Kerry Collier; Ephraim Hochberg; Philippe Armand; Tracy T Batchelor; Yi-Bin Chen; Zachariah DeFilipp
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-08-15

6.  Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres.

Authors:  Livio Pagano; Luana Fianchi; Luca Mele; Corrado Girmenia; Massimo Offidani; Paolo Ricci; Maria E Mitra; Marco Picardi; Cecilia Caramatti; Paolo Piccaluga; Annamaria Nosari; Massimo Buelli; Bernardino Allione; Agostino Cortelezzi; Francesco Fabbiano; Giuseppe Milone; Rosangela Invernizzi; Bruno Martino; Luciano Masini; Giuseppe Todeschini; Maria A Cappucci; Domenico Russo; Laura Corvatta; Pietro Martino; Albano Del Favero
Journal:  Br J Haematol       Date:  2002-05       Impact factor: 6.998

7.  Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.

Authors:  Francisco M Marty; Per Ljungman; Roy F Chemaly; Johan Maertens; Sanjeet S Dadwal; Rafael F Duarte; Shariq Haider; Andrew J Ullmann; Yuta Katayama; Janice Brown; Kathleen M Mullane; Michael Boeckh; Emily A Blumberg; Hermann Einsele; David R Snydman; Yoshinobu Kanda; Mark J DiNubile; Valerie L Teal; Hong Wan; Yoshihiko Murata; Nicholas A Kartsonis; Randi Y Leavitt; Cyrus Badshah
Journal:  N Engl J Med       Date:  2017-12-06       Impact factor: 91.245

8.  Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

Authors:  Carole Soussain; Khê Hoang-Xuan; Luc Taillandier; Emmanuelle Fourme; Sylvain Choquet; Francis Witz; Olivier Casasnovas; Brigitte Dupriez; Bertrand Souleau; Anne-Laure Taksin; Christian Gisselbrecht; Arnaud Jaccard; Antonio Omuro; Marc Sanson; Maud Janvier; Brigitte Kolb; Jean-Marc Zini; Véronique Leblond
Journal:  J Clin Oncol       Date:  2008-04-14       Impact factor: 44.544

9.  Steroid-Based Therapy and Risk of Infectious Complications.

Authors:  Lionel Rostaing; Paolo Malvezzi
Journal:  PLoS Med       Date:  2016-05-24       Impact factor: 11.069

10.  Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.

Authors:  Andrew J Ullmann; Martin Schmidt-Hieber; Hartmut Bertz; Werner J Heinz; Michael Kiehl; William Krüger; Sabine Mousset; Stefan Neuburger; Silke Neumann; Olaf Penack; Gerda Silling; Jörg Janne Vehreschild; Hermann Einsele; Georg Maschmeyer
Journal:  Ann Hematol       Date:  2016-06-24       Impact factor: 3.673

View more
  2 in total

1.  Effects of thioTEPA chemotherapy on cognition and motor coordination.

Authors:  Tyler C Alexander; Frederico Kiffer; Thomas Groves; Julie Anderson; Jing Wang; Abdallah Hayar; Michelle T Chen; Analiz Rodriguez; Antiño R Allen
Journal:  Synapse       Date:  2019-03-14       Impact factor: 2.562

2.  Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

Authors:  Michael Scordo; Trent P Wang; Kwang W Ahn; Yue Chen; Sairah Ahmed; Farrukh T Awan; Amer Beitinjaneh; Andy Chen; Victor A Chow; Bhagirathbhai Dholaria; Narendranath Epperla; Umar Farooq; Nilanjan Ghosh; Natalie Grover; Nada Hamad; Gerhard C Hildebrandt; Leona Holmberg; Sanghee Hong; David J Inwards; Antonio Jimenez-Jimenez; Reem Karmali; Vaishalee P Kenkre; Farhad Khimani; Evgeny Klyuchnikov; Maxwell M Krem; Pashna N Munshi; Yago Nieto; Tim Prestidge; Praveen Ramakrishnan Geethakumari; Andrew R Rezvani; Peter A Riedell; Sachiko Seo; Nirav N Shah; Melhem Solh; Jean A Yared; Mohamed A Kharfan-Dabaja; Alex Herrera; Mehdi Hamadani; Craig S Sauter
Journal:  JAMA Oncol       Date:  2021-07-01       Impact factor: 31.777

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.